# Rhett P Ketterling

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 462 papers | 14,515 citations | 57 h-index | 110 g-index |
| 465 ext. papers | 16,985 ext. citations | 4.5 avg, IF | 6 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 462 | Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *New England Journal of Medicine*, **2012**, 366, 1079-89 | 59.2 | 1378 |
| 461 | Anthracycline dose intensification in acute myeloid leukemia. *New England Journal of Medicine*, **2009**, 361, 1249-59 | 59.2 | 658 |
| 460 | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood*, **2014**, 124, 2507-13; quiz 2615 | 2.2 | 424 |
| 459 | CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. *Blood*, **2003**, 102, 3093-6 | 2.2 | 327 |
| 458 | Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. *Blood*, **2005**, 105, 973-7 | 2.2 | 305 |
| 457 | Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. *American Journal of Human Genetics*, **2003**, 73, 1027-40 | 11 | 298 |
| 456 | ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood*, **2014**, 124, 1473-80 | 2.2 | 294 |
| 455 | T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*, **2009**, 114, 5136-45 | 2.2 | 277 |
| 454 | FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. *Blood*, **2004**, 104, 3038-45 | 2.2 | 248 |
| 453 | MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. *Journal of Clinical Oncology*, **2018**, 36, 310-318 | 2.2 | 224 |
| 452 | Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood*, **2006**, 108, 1158-64 | 2.2 | 211 |
| 451 | Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. *Journal of Clinical Oncology*, **2014**, 32, 1242-8 | 2.2 | 187 |
| 450 | ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. *Leukemia*, **2014**, 28, 2206-12 | 10.7 | 186 |
| 449 | Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*, **2012**, 119, 2100-5 | 2.2 | 181 |
| 448 | HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2010**, 28, 4307-15 | 2.2 | 175 |
| 447 | SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. *Blood*, **2012**, 119, 569-72 | 2.2 | 164 |
| 446 | Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. *Blood*, **2012**, 120, 2280-9 | 2.2 | 164 |

| | | | |
|---|---|---|---|
| 445 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances*, **2016**, 1, 21-30 | 7.8 | 163 |
| 444 | Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. *Blood*, **2010**, 116, 4077-85 | 2.2 | 157 |
| 443 | Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. *Leukemia*, **2013**, 27, 1504-10 | 10.7 | 151 |
| 442 | Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. *American Journal of Hematology*, **2014**, 89, E121-4 | 7.1 | 145 |
| 441 | Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. *Human Molecular Genetics*, **1994**, 3, 1035-9 | 5.6 | 144 |
| 440 | One thousand patients with primary myelofibrosis: the mayo clinic experience. *Mayo Clinic Proceedings*, **2012**, 87, 25-33 | 6.4 | 137 |
| 439 | Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. *Modern Pathology*, **2011**, 24, 1421-32 | 9.8 | 135 |
| 438 | Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. *Cancer*, **2007**, 109, 2279-84 | 6.4 | 132 |
| 437 | SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. *Blood*, **2012**, 120, 4168-71 | 2.2 | 128 |
| 436 | Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. *American Journal of Surgical Pathology*, **2013**, 37, 1173-81 | 6.7 | 125 |
| 435 | Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. *Blood*, **2012**, 120, 1290-8 | 2.2 | 123 |
| 434 | Targeted deep sequencing in primary myelofibrosis. *Blood Advances*, **2016**, 1, 105-111 | 7.8 | 120 |
| 433 | GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. *Leukemia*, **2018**, 32, 1631-1642 | 10.7 | 117 |
| 432 | Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. *American Journal of Hematology*, **2013**, 88, 201-6 | 7.1 | 112 |
| 431 | Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. *Leukemia*, **2012**, 26, 101-5 | 10.7 | 112 |
| 430 | FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. *Leukemia Research*, **2006**, 30, 965-70 | 2.7 | 110 |
| 429 | The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood*, **2014**, 124, 2465-6 | 2.2 | 105 |
| 428 | Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. *American Journal of Hematology*, **2014**, 89, 1111-5 | 7.1 | 104 |

| | | | |
|---|---|---|---|
| 427 | Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. *Blood*, **2005**, 106, 3553-8 | 2.2 | 100 |
| 426 | Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2016**, 6, e385 | 7 | 83 |
| 425 | Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. *Modern Pathology* , **2007**, 20, 592-603 | 9.8 | 83 |
| 424 | Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265 | 13.4 | 82 |
| 423 | Preclinical validation of fluorescence in situ hybridization assays for clinical practice. *Genetics in Medicine*, **2006**, 8, 16-23 | 8.1 | 81 |
| 422 | Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. *Blood*, **2016**, 127, 1551-8 | 2.2 | 81 |
| 421 | Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*, **2009**, 94, 380-6 | 6.6 | 80 |
| 420 | CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. *Blood*, **2012**, 120, 2297-306 | 2.2 | 78 |
| 419 | SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. *Leukemia*, **2013**, 27, 2100-2 | 10.7 | 75 |
| 418 | Analysis of Intratumoral Heterogeneity and Amplification Status in Breast Carcinomas With Equivocal (2+) HER-2 Immunostaining. *American Journal of Clinical Pathology*, **2005**, 124, 273-281 | 1.9 | 73 |
| 417 | WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. *Leukemia*, **2010**, 24, 1283-9 | 10.7 | 72 |
| 416 | Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discovery*, **2012**, 2, 1004-23 | 24.4 | 70 |
| 415 | Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. *American Journal of Surgical Pathology*, **2016**, 40, 36-43 | 6.7 | 70 |
| 414 | and rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. *Blood*, **2017**, 130, 554-557 | 2.2 | 68 |
| 413 | Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. *Leukemia*, **2018**, 32, 1200-1210 | 10.7 | 68 |
| 412 | Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. *Journal of Clinical Oncology*, **2016**, 34, 3502-3510 | 2.2 | 68 |
| 411 | Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. *Leukemia*, **2018**, 32, 1189-1199 | 10.7 | 65 |
| 410 | Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. *Blood*, **2018**, 132, 544-547 | 2.2 | 60 |

| | | | |
|---|---|---|---|
| 409 | Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation. *American Journal of Surgical Pathology*, **2013**, 37, 978-86 | 6.7 | 60 |
| 408 | Molecular diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. *Diagnostic Molecular Pathology*, **2005**, 14, 23-8 | | 60 |
| 407 | Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. *Blood*, **2012**, 119, 5674-7 | 2.2 | 59 |
| 406 | Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. *British Journal of Haematology*, **2020**, 189, 291-302 | 4.5 | 58 |
| 405 | Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH. *Leukemia Research*, **2002**, 26, 235-40 | 2.7 | 57 |
| 404 | Rosette-forming glioneuronal tumor: report of a chiasmal-optic nerve example in neurofibromatosis type 1: special pathology report. *Neurosurgery*, **2009**, 64, E771-2; discussion E772 | 3.2 | 56 |
| 403 | Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. *European Journal of Haematology*, **2008**, 80, 197-200 | 3.8 | 56 |
| 402 | Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. *Stem Cells*, **2007**, 25, 2358-62 | 5.8 | 55 |
| 401 | Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. *American Journal of Hematology*, **2016**, 91, 492-8 | 7.1 | 55 |
| 400 | Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. *Blood Advances*, **2018**, 2, 370-380 | 7.8 | 55 |
| 399 | Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. *Blood*, **2008**, 112, 1931-41 | 2.2 | 54 |
| 398 | Evidence that descendants of three founders constitute about 25% of hemophilia B in the United States. *Genomics*, **1991**, 10, 1093-6 | 4.3 | 54 |
| 397 | Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. *American Journal of Hematology*, **2018**, 93, 348-355 | 7.1 | 54 |
| 396 | Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. *Blood*, **2011**, 117, 5306-13 | 2.2 | 53 |
| 395 | Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. *European Journal of Haematology*, **2009**, 83, 17-21 | 3.8 | 53 |
| 394 | Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. *Mayo Clinic Proceedings*, **2010**, 85, 532-7 | 6.4 | 52 |
| 393 | Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. *Genetics in Medicine*, **2011**, 13, 667-75 | 8.1 | 52 |
| 392 | Reflex fluorescent in situ hybridization testing for unsuccessful product of conception cultures: a retrospective analysis of 5555 samples attempted by conventional cytogenetics and fluorescent in situ hybridization. *Genetics in Medicine*, **2011**, 13, 545-52 | 8.1 | 52 |

| | | | |
|---|---|---|---|
| 391 | New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia. *Cancer Genetics and Cytogenetics*, **2003**, 145, 144-51 | | 52 |
| 390 | Pituitary blastoma. *Acta Neuropathologica*, **2008**, 116, 657-66 | 14.3 | 51 |
| 389 | 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Mayo Clinic Proceedings*, **2019**, 94, 599-610 | 6.4 | 50 |
| 388 | Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R. *American Journal of Hematology*, **2017**, 92, 1311-1317 | 7.1 | 50 |
| 387 | Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *British Journal of Haematology*, **2016**, 172, 384-91 | 4.5 | 49 |
| 386 | Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization. *Journal of the American Academy of Dermatology*, **2014**, 70, 1021-7 | 4.5 | 49 |
| 385 | C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. *Journal of Clinical Oncology*, **2011**, 29, 651-9 | 2.2 | 49 |
| 384 | Utility of subtelomeric fluorescent DNA probes for detection of chromosome anomalies in 425 patients. *Genetics in Medicine*, **2003**, 5, 28-34 | 8.1 | 49 |
| 383 | DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. *American Journal of Hematology*, **2017**, 92, 56-61 | 7.1 | 48 |
| 382 | U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia*, **2018**, 32, 2274-2278 | 10.7 | 47 |
| 381 | The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-B positive feedback loop in peripheral T-cell lymphoma. *Blood*, **2015**, 125, 3118-27 | 2.2 | 47 |
| 380 | Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. *European Journal of Haematology*, **2009**, 82, 255-9 | 3.8 | 47 |
| 379 | Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival. *American Journal of Hematology*, **2016**, 91, 888-93 | 7.1 | 47 |
| 378 | Treatment-influenced associations of PML-RAR mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. *Blood*, **2012**, 120, 2098-108 | 2.2 | 46 |
| 377 | Recurrent fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. *Blood* , **2018**, 131, 2262-2266 | 2.2 | 45 |
| 376 | Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. *American Journal of Hematology*, **2018**, 93, 1074-1081 | 7.1 | 45 |
| 375 | Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome. *American Journal of Hematology*, **2015**, 90, 411-6 | 7.1 | 45 |
| 374 | Pediatric histiocytic sarcoma clonally related to precursor B-cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16INK4A. *Pediatric Blood and Cancer*, **2011**, 56, 307-10 | 3 | 45 |

| | | | |
|---|---|---|---|
| 373 | Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. *Human Mutation*, **1999**, 13, 221-31 | 4.7 | 45 |
| 372 | Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with rearrangements. *Blood*, **2018**, 132, 1386-1398 | 2.2 | 44 |
| 371 | The factor IX gene as a model for analysis of human germline mutations: an update. *Human Molecular Genetics*, **1996**, 5 Spec No, 1505-14 | 5.6 | 43 |
| 370 | Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). *Leukemia*, **2010**, 24, 1370-2 | 10.7 | 42 |
| 369 | Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 542-548 | 7.1 | 41 |
| 368 | Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. *Blood Advances*, **2018**, 2, 2964-2972 | 7.8 | 40 |
| 367 | ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 623-6 | 5 | 39 |
| 366 | Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. *American Journal of Hematology*, **2018**, 93, 65-73 | 7.1 | 37 |
| 365 | The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. *Human Genetics*, **1993**, 91, 496-503 | 6.3 | 37 |
| 364 | Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. *American Journal of Hematology*, **2016**, 91, 503-6 | 7.1 | 37 |
| 363 | Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. *Blood*, **2013**, 122, e33-43 | 2.2 | 36 |
| 362 | Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. *Blood*, **2011**, 117, e190-7 | 2.2 | 36 |
| 361 | Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. *Human Pathology*, **2010**, 41, 103-6 | 3.7 | 36 |
| 360 | Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. *European Journal of Haematology*, **2015**, 94, 31-6 | 3.8 | 35 |
| 359 | Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. *Leukemia and Lymphoma*, **2017**, 58, 1488-1493 | 1.9 | 35 |
| 358 | Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia. *Blood Cancer Journal*, **2015**, 5, e275 | 7 | 35 |
| 357 | Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma. *Genes Chromosomes and Cancer*, **2006**, 45, 1111-20 | 5 | 35 |
| 356 | Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. *American Journal of Hematology*, **2018**, 93, 691-697 | 7.1 | 34 |

| | | | |
|---|---|---|---|
| 355 | Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders. *American Journal of Surgical Pathology*, **2014**, 38, 1203-11 | 6.7 | 34 |
| 354 | A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B. *British Journal of Haematology*, **1990**, 75, 212-6 | 4.5 | 33 |
| 353 | Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. *Human Pathology*, **2017**, 64, 19-27 | 3.7 | 31 |
| 352 | Monocytosis in polycythemia vera: Clinical and molecular correlates. *American Journal of Hematology*, **2017**, 92, 640-645 | 7.1 | 31 |
| 351 | Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements. *Haematologica*, **2018**, 103, 1899-1907 | 6.6 | 31 |
| 350 | Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution. *American Journal of Hematology*, **2010**, 85, 238-42 | 7.1 | 31 |
| 349 | Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. *American Journal of Hematology*, **2018**, 93, 1474-1484 | 7.1 | 31 |
| 348 | EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. *Blood Cancer Journal*, **2018**, 8, 12 | 7 | 30 |
| 347 | Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. *American Journal of Clinical Pathology* , **2011**, 135, 686-96 | 1.9 | 30 |
| 346 | Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. *American Journal of Hematology*, **2013**, 88, 690-3 | 7.1 | 29 |
| 345 | t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. *PLoS ONE*, **2013**, 8, e53767 | 3.7 | 29 |
| 344 | Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. *Cancer Research*, **2009**, 69, 7518-23 | 10.1 | 29 |
| 343 | Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. *Blood Cancer Journal*, **2019**, 9, 12 | 7 | 28 |
| 342 | Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2009**, 454, 431-9 | 5.1 | 28 |
| 341 | CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma. *Human Pathology*, **2009**, 40, 1296-303 | 3.7 | 28 |
| 340 | Functioning paraganglioma and gastrointestinal stromal tumor of the jejunum in three women: syndrome or coincidence. *American Journal of Surgical Pathology*, **2006**, 30, 42-9 | 6.7 | 28 |
| 339 | Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians. *Human Molecular Genetics*, **1993**, 2, 293-8 | 5.6 | 28 |
| 338 | Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. *American Journal of Hematology*, **2019**, 94, 767-779 | 7.1 | 27 |

| | | | |
|---|---|---|---|
| 337 | Momelotinib therapy for myelofibrosis: a 7-year follow-up. *Blood Cancer Journal*, **2018**, 8, 29 | 7 | 27 |
| 336 | Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. *American Journal of Clinical Pathology*, **2009**, 131, 663-70 | 1.9 | 27 |
| 335 | Inherited interstitial deletion of chromosomes 5p and 16q without apparent phenotypic effect: further confirmation. *Prenatal Diagnosis*, **2000**, 20, 144-8; discussion 149-51 | 3.2 | 27 |
| 334 | Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519 | 7.8 | 27 |
| 333 | Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. *Leukemia*, **2018**, 32, 1254-1258 | 10.7 | 26 |
| 332 | Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. *American Journal of Hematology*, **2018**, 93, 649-654 | 7.1 | 26 |
| 331 | A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients. *British Journal of Haematology*, **2015**, 169, 71-6 | 4.5 | 26 |
| 330 | Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases. *Leukemia Research*, **2010**, 34, e71-3 | 2.7 | 25 |
| 329 | Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception. *American Journal of Clinical Pathology*, **2010**, 133, 196-204 | 1.9 | 24 |
| 328 | Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. *American Journal of Clinical Pathology*, **2012**, 137, 270-6 | 1.9 | 24 |
| 327 | Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. *American Journal of Clinical Pathology*, **2008**, 129, 478-85 | 1.9 | 24 |
| 326 | Recurrent mutations in ALK-negative anaplastic large cell lymphoma. *Blood*, **2019**, 133, 2776-2789 | 2.2 | 23 |
| 325 | Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. *Cancer Epidemiology*, **2015**, 39, 1084-92 | 2.8 | 23 |
| 324 | Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis. *British Journal of Haematology*, **2018**, 183, 835-838 | 4.5 | 23 |
| 323 | An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. *Leukemia Research*, **2007**, 31, 1145-8 | 2.7 | 23 |
| 322 | Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 102, 87-96 | 3.8 | 23 |
| 321 | Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32 | 7 | 22 |
| 320 | Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. *Journal of Clinical Oncology*, **2012**, 30, 1087-94 | 2.2 | 22 |

| | | | |
|---|---|---|---|
| 319 | Splenic small B-cell lymphoma with IGH/BCL3 translocation. *Human Pathology*, **2006**, 37, 218-30 | 3.7 | 22 |
| 318 | Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. *Blood Cancer Journal*, **2015**, 5, e270 | 7 | 21 |
| 317 | Isochromosome 12p and polysomy 12 in primary central nervous system germ cell tumors: frequency and association with clinicopathologic features. *Human Pathology*, **2010**, 41, 232-8 | 3.7 | 21 |
| 316 | Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. *European Journal of Haematology*, **2010**, 84, 191-200 | 3.8 | 21 |
| 315 | Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. *European Journal of Haematology*, **2010**, 84, 518-24 | 3.8 | 21 |
| 314 | Deletions with inversions: report of a mutation and review of the literature. *Human Mutation*, **1993**, 2, 53-7 | 4.7 | 21 |
| 313 | Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. *American Journal of Hematology*, **2017**, 92, E614-E618 | 7.1 | 20 |
| 312 | Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938 | 7.8 | 20 |
| 311 | A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. *Leukemia*, **2018**, 32, 1850-1856 | 10.7 | 19 |
| 310 | Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. *Leukemia*, **2018**, 32, 2512-2518 | 10.7 | 19 |
| 309 | Evaluation of a commercially available focused aCGH platform for the detection of constitutional chromosome anomalies. *American Journal of Medical Genetics, Part A*, **2007**, 143A, 2357-70 | 2.5 | 19 |
| 308 | Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. *American Journal of Clinical Pathology*, **2005**, 124, 273-81 | 1.9 | 19 |
| 307 | ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. *British Journal of Haematology*, **2016**, 175, 534-536 | 4.5 | 19 |
| 306 | A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. *American Journal of Hematology*, **2019**, 94, 111-117 | 7.1 | 19 |
| 305 | Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. *Annals of Hematology*, **2018**, 97, 1453-1462 | 3 | 18 |
| 304 | Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815 | 10.7 | 18 |
| 303 | Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. *British Journal of Haematology*, **2018**, 182, 594-597 | 4.5 | 18 |
| 302 | Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients. *American Journal of Hematology*, **2017**, 92, 1193-1197 | 7.1 | 18 |

| | | | |
|---|---|---|---|
| 301 | Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. *American Journal of Hematology*, **2011**, 86, 393-8 | 7.1 | 18 |
| 300 | Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. *Leukemia and Lymphoma* , **2006**, 47, 2055-61 | 1.9 | 18 |
| 299 | A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B. *Human Molecular Genetics*, **1993**, 2, 1309-10 | 5.6 | 18 |
| 298 | Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 103 | 7 | 18 |
| 297 | Mutations and karyotype predict treatment response in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, 1420-1426 | 7.1 | 18 |
| 296 | Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 57 | 7 | 17 |
| 295 | Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. *American Journal of Hematology*, **2018**, 93, 1461-1466 | 7.1 | 17 |
| 294 | Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis. *American Journal of Hematology*, **2017**, 92, 1187-1192 | 7.1 | 17 |
| 293 | Familial 22q11.2 deletions in DiGeorge/velocardiofacial syndrome are predominantly smaller than the commonly observed 3Mb. *Genetics in Medicine*, **2004**, 6, 517-20 | 8.1 | 17 |
| 292 | Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82 | 7 | 17 |
| 291 | Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. *Leukemia*, **2020**, 34, 656-661 | 10.7 | 17 |
| 290 | Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia. *American Journal of Clinical Pathology*, **2015**, 143, 873-8 | 1.9 | 16 |
| 289 | The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. *International Journal of Cancer*, **2011**, 128, 2759-64 | 7.5 | 16 |
| 288 | Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2005**, 129, 45-52 | 4.5 | 16 |
| 287 | KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. *Genes Chromosomes and Cancer*, **2018**, 57, 541-546 | 5 | 16 |
| 286 | Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. *Leukemia Research*, **2017**, 59, 55-64 | 2.7 | 15 |
| 285 | Development of a dual-color, double fusion FISH assay to detect RPN1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia. *American Journal of Hematology*, **2010**, 85, 569-74 | 7.1 | 15 |
| 284 | Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. *Leukemia Research*, **2008**, 32, 1927-30 | 2.7 | 15 |

| | | | |
|---|---|---|---|
| 283 | How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lesions from the human factor IX gene. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1994**, 307, 517-31 | 3.3 | 15 |
| 282 | Molecular Epidemiology of Factor IX Germline Mutations in Mexican Hispanics: Pattern of Mutation and Potential Founder Effects. *Thrombosis and Haemostasis*, **1995**, 74, 1416-1422 | 7 | 15 |
| 281 | Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. *British Journal of Haematology*, **2018**, 182, 437-440 | 4.5 | 14 |
| 280 | Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. *Mayo Clinic Proceedings*, **2018**, 93, 1363-1374 | 6.4 | 14 |
| 279 | Atypical generalized eruptive histiocytosis clonally related to chronic myelomonocytic leukemia with loss of Y chromosome. *Journal of Cutaneous Pathology*, **2013**, 40, 725-9 | 1.7 | 14 |
| 278 | Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. *Leukemia Research*, **2009**, 33, 843-6 | 2.7 | 14 |
| 277 | Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. *Blood*, **2009**, 113, 1200-1 | 2.2 | 14 |
| 276 | Nearly identical near-haploid karyotype in a peritoneal mesothelioma and a retroperitoneal malignant peripheral nerve sheath tumor. *Cancer Genetics and Cytogenetics*, **2010**, 202, 123-8 | | 14 |
| 275 | Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. *Leukemia Research*, **2008**, 32, 407-11 | 2.7 | 14 |
| 274 | Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system. *Journal of Molecular Diagnostics*, **2007**, 9, 144-50 | 5.1 | 14 |
| 273 | Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes. *American Journal of Clinical Pathology*, **2016**, 146, 86-94 | 1.9 | 14 |
| 272 | FISH identifies a KAT6A/CREBBP fusion caused by a cryptic insertional t(8;16) in a case of spontaneously remitting congenital acute myeloid leukemia with a normal karyotype. *Pediatric Blood and Cancer*, **2017**, 64, e26450 | 3 | 13 |
| 271 | Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. *Blood Cancer Journal*, **2018**, 8, 18 | 7 | 13 |
| 270 | LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma. *American Journal of Clinical Pathology*, **2016**, 145, 180-90 | 1.9 | 13 |
| 269 | Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q). *Blood Cancer Journal*, **2017**, 7, 658 | 7 | 13 |
| 268 | Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. *Cancer Genetics and Cytogenetics* , **2007**, 175, 8-18 | | 13 |
| 267 | Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the V617F mutation. *Haematologica*, **2019**, 104, e236-e239 | 6.6 | 13 |
| 266 | MPL-mutated essential thrombocythemia: a morphologic reappraisal. *Blood Cancer Journal*, **2018**, 8, 1217 | | 13 |

| | | | |
|---|---|---|---|
| 265 | A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. *American Journal of Surgical Pathology*, **2013**, 37, 147-51 | 6.7 | 12 |
| 264 | A novel report of cig-FISH and cytogenetics in POEMS syndrome. *American Journal of Hematology*, **2008**, 83, 840-1 | 7.1 | 12 |
| 263 | Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. *Leukemia Research*, **2018**, 71, 60-62 | 2.7 | 11 |
| 262 | Clinicopathologic and genetic characterization of follicular lymphomas presenting in the ovary reveals 2 distinct subgroups. *American Journal of Surgical Pathology*, **2011**, 35, 1691-9 | 6.7 | 11 |
| 261 | Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. *Pediatric Blood and Cancer*, **2011**, 56, 467-9 | 3 | 11 |
| 260 | Two novel factor IX promoter mutations: incremental progress towards 'saturation in vivo mutagenesis' of a human promoter region. *Human Molecular Genetics*, **1995**, 4, 769-70 | 5.6 | 11 |
| 259 | Concurrent activating KIT mutations in systemic mastocytosis. *British Journal of Haematology*, **2016**, 173, 153-6 | 4.5 | 11 |
| 258 | Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory. *Genes Chromosomes and Cancer*, **2019**, 58, 567-577 | 5 | 11 |
| 257 | Characterization of a cryptic rearrangement in a case of mantle cell lymphoma with negative FISH studies. *Blood Advances*, **2019**, 3, 1298-1302 | 7.8 | 11 |
| 256 | Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. *Modern Pathology*, **2015**, 28, 359-66 | 9.8 | 10 |
| 255 | Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. *Mayo Clinic Proceedings*, **2015**, 90, 1623-38 | 6.4 | 10 |
| 254 | Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. *American Journal of Clinical Pathology*, **2015**, 144, 493-502 | 1.9 | 10 |
| 253 | High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. *Blood Cancer Journal*, **2020**, 10, 5 | 7 | 10 |
| 252 | Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients. *Leukemia Research*, **2012**, 36, 59-66 | 2.7 | 10 |
| 251 | TP53 mutations and polymorphisms in primary myelofibrosis. *American Journal of Hematology*, **2012**, 87, 204-6 | 7.1 | 10 |
| 250 | Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 699-704 | 2 | 10 |
| 249 | Microgranular variant of acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR. *Cancer Genetics*, **2011**, 204, 522-3 | 2.3 | 10 |
| 248 | Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. *European Journal of Haematology*, **2010**, 85, 86-7 | 3.8 | 10 |

| | | | |
|---|---|---|---|
| 247 | Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern. *Human Mutation*, **1998**, 11, 372-6 | 4.7 | 10 |
| 246 | Comprehensive validation of array comparative genomic hybridization platforms: how much is enough?. *Genetics in Medicine*, **2007**, 9, 632-41 | 8.1 | 10 |
| 245 | Absence of somatic mosaicism in 17 families with hemophilia B: an analysis with a sensitivity 10- to 1000-fold greater than that of sequencing gels. *Human Genetics*, **1996**, 98, 539-45 | 6.3 | 10 |
| 244 | "Cryptic" dinucleotide polymorphism in the 3' region of the factor IX gene shows substantial variation among different populations. *Human Genetics*, **1994**, 93, 357-8 | 6.3 | 10 |
| 243 | Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. *British Journal of Haematology*, **2018**, 183, 678-681 | 4.5 | 10 |
| 242 | Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms. *Blood Cancer Journal*, **2018**, 8, 32 | 7 | 9 |
| 241 | The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms: An ACLPS Critical Review. *American Journal of Clinical Pathology*, **2018**, 150, 375-384 | 1.9 | 9 |
| 240 | Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. *Blood Cancer Journal*, **2019**, 9, 81 | 7 | 9 |
| 239 | Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. *Journal of Molecular Diagnostics*, **2010**, 12, 441-52 | 5.1 | 9 |
| 238 | Targeted Next-Generation Sequencing in Polycythemia Vera and Essential Thrombocythemia. *Blood* , **2015**, 126, 354-354 | 2.2 | 9 |
| 237 | Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. *International Journal of Clinical and Experimental Pathology* , **2012**, 5, 72-6 | 1.4 | 9 |
| 236 | Application of thrombolytic drugs on clotted blood and bone marrow specimens to generate usable cells for cytogenetic analyses. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 915-9 | 5 | 9 |
| 235 | Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588 | 12.9 | 9 |
| 234 | A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). *American Journal of Hematology*, **2016**, 91, 308-12 | 7.1 | 9 |
| 233 | Elucidating a false-negative break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with and rearrangements. *Journal of Physical Education and Sports Management*, **2019**, 5, | 2.8 | 8 |
| 232 | Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260 | 4.5 | 8 |
| 231 | A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy. *Blood Cancer Journal*, **2019**, 9, 11 | 7 | 8 |
| 230 | Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. *Blood Advances*, **2018**, 2, 1980-1984 | 7.8 | 8 |

| | | | |
|---|---|---|---|
| 229 | Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 580-9 | 1.9 | 8 |
| 228 | Cutaneous extramedullary plasmacytoma: clinical, prognostic, and interphase cytogenetic analysis. *American Journal of Dermatopathology*, **2013**, 35, 357-63 | 0.9 | 8 |
| 227 | Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. *American Journal of Hematology*, **2018**, 93, E235-E238 | 7.1 | 7 |
| 226 | Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. *American Journal of Hematology*, **2018**, 93, 1347-1357 | 7.1 | 7 |
| 225 | A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited. *American Journal of Surgical Pathology*, **2011**, 35, 1080-4 | 6.7 | 7 |
| 224 | Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. *European Journal of Haematology*, **2008**, 80, 318-21 | 3.8 | 7 |
| 223 | Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244 | 7.8 | 7 |
| 222 | Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. *Blood*, **2021**, 138, 948-958 | 2.2 | 7 |
| 221 | Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. *American Journal of Hematology*, **2019**, 94, E117-E120 | 7.1 | 6 |
| 220 | Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. *Blood Cancer Journal*, **2019**, 9, 20 | 7 | 6 |
| 219 | Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. *American Journal of Clinical Pathology*, **2020**, 153, 656-663 | 1.9 | 6 |
| 218 | A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow: A Single Institutional Experience. *American Journal of Clinical Pathology*, **2018**, 150, 421-431 | 1.9 | 6 |
| 217 | The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. *Blood*, **2017**, 130, 822-822 | 2.2 | 6 |
| 216 | Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. *Human Pathology*, **2019**, 89, 109-114 | 3.7 | 6 |
| 215 | Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. *Leukemia*, **2021**, 35, 644-649 | 10.7 | 6 |
| 214 | Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. *Human Pathology*, **2017**, 64, 207-212 | 3.7 | 5 |
| 213 | Combined Tumors in Hematolymphoid Neoplasms: Case Series of Histiocytic and Langerhans Cell Sarcomas Arising From Low-Grade B-Cell Lymphoma. *BMC Clinical Pathology*, **2019**, 12, 2632010X19878410 | 1.2 | 5 |
| 212 | The significance of genetic mutations and their prognostic impact on patients with incidental finding of isolated del(20q) in bone marrow without morphologic evidence of a myeloid neoplasm. *Blood Cancer Journal*, **2020**, 10, 7 | 7 | 5 |

| | | | |
|---|---|---|---|
| 211 | FGFR1 rearranged hematological neoplasms - molecularly defined and clinically heterogeneous. *Leukemia and Lymphoma*, **2018**, 59, 1520-1522 | 1.9 | 5 |
| 210 | Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. *Leukemia and Lymphoma*, **2018**, 59, 2998-3001 | 1.9 | 5 |
| 209 | Is It Time for a New Gold Standard? FISH vs Cytogenetics in AML Diagnosis. *American Journal of Clinical Pathology*, **2016**, 145, 430-2 | 1.9 | 5 |
| 208 | A leukemic presentation of a "triple-hit" lymphoma. *Blood*, **2014**, 123, 1126 | 2.2 | 5 |
| 207 | Development of an NPM1/MLF1 D-FISH probe set for the detection of t(3;5)(q25;q35) identified in patients with acute myeloid leukemia. *Journal of Molecular Diagnostics*, **2014**, 16, 527-532 | 5.1 | 5 |
| 206 | Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates. *Blood Cancer Journal*, **2017**, 7, 657 | 7 | 5 |
| 205 | Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. *Leukemia Research*, **2008**, 32, 1597-600 | 2.7 | 5 |
| 204 | Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). *Blood*, **2018**, 132, 578-578 | 2.2 | 5 |
| 203 | Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. *Blood*, **2015**, 126, 1308-1308 | 2.2 | 5 |
| 202 | SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. *Blood Advances*, **2020**, 4, 5716-5721 | 7.8 | 5 |
| 201 | Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430 | 7.1 | 5 |
| 200 | The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. *American Journal of Hematology*, **2019**, 94, 299-305 | 7.1 | 5 |
| 199 | The Prognostic Role of Structural Variants Identified by NGS and FISH in Multiple Myeloma. *Clinical Cancer Research*, **2021**, | 12.9 | 5 |
| 198 | CD36-positive B-lymphoblasts Predict Poor Outcome in Children With B-lymphoblastic Leukemia. *Pediatric and Developmental Pathology*, **2017**, 20, 224-231 | 2.2 | 4 |
| 197 | A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21 | 7 | 4 |
| 196 | Decreased Levels of Total or HDL Cholesterol in Primary Myelofibrosis Are Associated with Shortened Survival: DIPSS-Plus Independent Prognostic Value.. *Blood*, **2012**, 120, 2851-2851 | 2.2 | 4 |
| 195 | Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. *Blood*, **2016**, 128, 1123-1123 | 2.2 | 4 |
| 194 | Characterization of a cryptic fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative FISH studies. *Leukemia and Lymphoma*, **2020**, 61, 975-978 | 1.9 | 4 |

| | | | |
|---|---|---|---|
| 193 | Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. *Leukemia Research*, **2016**, 50, 112-115 | 2.7 | 4 |
| 192 | Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. *Haematologica*, **2019**, 104, e147-e150 | 6.6 | 4 |
| 191 | Constitutional chromosome rearrangements that mimic the 2017 world health organization "acute myeloid leukemia with recurrent genetic abnormalities": A study of three cases and review of the literature. *Cancer Genetics*, **2019**, 230, 37-46 | 2.3 | 4 |
| 190 | Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. *Genes Chromosomes and Cancer*, **2020**, 59, 422-427 | 5 | 4 |
| 189 | Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. *Annals of Diagnostic Pathology*, **2020**, 46, 151533 | 2.2 | 3 |
| 188 | Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement. *Cancer Genetics*, **2018**, 220, 13-18 | 2.3 | 3 |
| 187 | Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. *Cancer Genetics*, **2019**, 237, 51-54 | 2.3 | 3 |
| 186 | Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. *American Journal of Clinical Pathology*, **2020**, 153, 333-341 | 1.9 | 3 |
| 185 | Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. *Blood*, **2013**, 122, 104-104 | 2.2 | 3 |
| 184 | Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. *Blood*, **2016**, 128, 2798-2798 | 2.2 | 3 |
| 183 | Identification of t(1;19)(q12;p13) and ploidy changes in an ependymosarcoma: a cytogenetic evaluation **2012**, 31, 142-5 | | 3 |
| 182 | Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma. *American Journal of Surgical Pathology*, **2021**, 45, 550-557 | 6.7 | 3 |
| 181 | Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.. *Blood*, **2009**, 114, 3937-3937 | 2.2 | 3 |
| 180 | Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. *Cancer Genetics*, **2020**, 240, 40-44 | 2.3 | 3 |
| 179 | Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA  venetoclax chemotherapy. *American Journal of Hematology*, **2021**, 96, E108-E111 | 7.1 | 3 |
| 178 | Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. *Blood Advances*, **2021**, 5, 2272-2278 | 7.8 | 3 |
| 177 | 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. *American Journal of Hematology*, **2019**, 94, 286-290 | 7.1 | 3 |
| 176 | Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. *American Journal of Hematology*, **2019**, 94, 5-9 | 7.1 | 3 |

| | | | |
|---|---|---|---|
| 175 | Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. *Histopathology*, **2020**, 76, 481-485 | 7.3 | 3 |
| 174 | Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. *Blood Cancer Journal*, **2021**, 11, 18 | 7 | 3 |
| 173 | Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates. *Blood Cancer Journal*, **2018**, 8, 118 | 7 | 3 |
| 172 | Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. *Blood Cancer Journal*, **2021**, 11, 156 | 7 | 3 |
| 171 | The 2016 revised World Health Organization definition of 'myelodysplastic syndrome with isolated del(5q)'; prognostic implications of single versus double cytogenetic abnormalities. *British Journal of Haematology*, **2017**, 178, 57-60 | 4.5 | 2 |
| 170 | Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients. *American Journal of Hematology*, **2020**, 95, E86-E89 | 7.1 | 2 |
| 169 | Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. *Cancer Genetics*, **2020**, 243, 48-51 | 2.3 | 2 |
| 168 | Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 598-602 | 2 | 2 |
| 167 | Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 1534-7 | 1.9 | 2 |
| 166 | When are apparently non-clonal abnormalities in bone marrow chromosome studies actually clonal?. *Cancer Genetics*, **2012**, 205, 405-9 | 2.3 | 2 |
| 165 | Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. *Leukemia and Lymphoma*, **2007**, 48, 2137-40 | 1.9 | 2 |
| 164 | Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. *British Journal of Haematology*, **2003**, 123, 366-7 | 4.5 | 2 |
| 163 | PRE: a novel element with the hallmarks of a retrotransposon derived from an unknown structural RNA. *Nucleic Acids Research*, **1992**, 20, 5233 | 20.1 | 2 |
| 162 | Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. *American Journal of Hematology*, **2021**, | 7.1 | 2 |
| 161 | ASXL1 and SETBP1 Mutations and Their Prognostic Contribution In Chronic Myelomonocytic Leukemia: An International Study Of 431 Patients. *Blood*, **2013**, 122, 1510-1510 | 2.2 | 2 |
| 160 | Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. *Blood*, **2013**, 122, 3210-3210 | 2.2 | 2 |
| 159 | ASXL1 and CBL Mutations Are Independently Predictive of Inferior Survival in Advanced Systemic Mastocytosis. *Blood*, **2015**, 126, 828-828 | 2.2 | 2 |
| 158 | Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". *Blood*, **2016**, 128, 1750-1750 | 2.2 | 2 |

| | | | |
|---|---|---|---|
| 157 | Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 3113-3113 | 2.2 | 2 |
| 156 | Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons. *Blood*, **2016**, 128, 4247-4247 | 2.2 | 2 |
| 155 | Monocytosis Is a Powerful and Independent Predictor of Shortened Overall and Leukemia-Free Survival in Primary Myelofibrosis. *Blood*, **2016**, 128, 4249-4249 | 2.2 | 2 |
| 154 | Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 176-190 | 5 | 2 |
| 153 | Discovery of 6 Novel Translocations Involving the Imatinib Responsive Genes PDGFRB and PDGFRB from Screening 29,047 Abnormal Bone Marrow Specimens.. *Blood*, **2004**, 104, 2902-2902 | 2.2 | 2 |
| 152 | Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. *American Journal of Hematology*, **2020**, 95, E68-E72 | 7.1 | 2 |
| 151 | Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. *Human Pathology*, **2021**, 112, 20-34 | 3.7 | 2 |
| 150 | Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. *Leukemia*, **2019**, 33, 780-785 | 10.7 | 2 |
| 149 | Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162 | 7.1 | 2 |
| 148 | Immunophenotypic and laboratory features of t(11;14)(q13;q32)-positive plasma cell neoplasms. *Leukemia and Lymphoma*, **2018**, 59, 1913-1919 | 1.9 | 2 |
| 147 | A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. *American Journal of Hematology*, **2018**, 93, E401-E404 | 7.1 | 2 |
| 146 | Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. *American Journal of Hematology*, **2018**, 93, E383-E386 | 7.1 | 2 |
| 145 | Cytogenetic clonal evolution in myeloproliferative neoplasms: contexts and prognostic impact among 648 patients with serial bone marrow biopsies. *Leukemia*, **2019**, 33, 2522-2553 | 10.7 | 1 |
| 144 | ADDENDUM: Section E9 of the American College of Medical Genetics Technical Standards and Guidelines: Fluorescence in situ hybridization. *Genetics in Medicine*, **2019**, 21, 2405 | 8.1 | 1 |
| 143 | A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia. *Genes Chromosomes and Cancer*, **2019**, 58, 665-668 | 5 | 1 |
| 142 | The impact of sex on disease phenotype and prognostic thresholds of anemia in myelodysplastic syndromes. *American Journal of Hematology*, **2018**, 93, E164-E167 | 7.1 | 1 |
| 141 | Revisiting the need for bone marrow examination in chronic myeloid leukemia. *American Journal of Hematology*, **2018**, 93, 5-7 | 7.1 | 1 |
| 140 | Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. *European Journal of Haematology*, **2013**, 91, 193-5 | 3.8 | 1 |

| | | | |
|---|---|---|---|
| 139 | Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. *Blood Cancer Journal*, **2022**, 12, 26 | 7 | 1 |
| 138 | -mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. *Haematologica*, **2022**, | 6.6 | 1 |
| 137 | 3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. *Blood*, **2018**, 132, 3035-3035 | 2.2 | 1 |
| 136 | Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study. *Blood*, **2018**, 132, 3040-3040 | 2.2 | 1 |
| 135 | 14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. *Blood*, **2007**, 110, 2477-2477 | 2.2 | 1 |
| 134 | R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. *Blood*, **2012**, 120, 676-676 | 2.2 | 1 |
| 133 | Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. *Blood*, **2013**, 122, 2821-2821 | 2.2 | 1 |
| 132 | Driver Mutations and Prognosis in 502 Patients with Essential Thrombocythemia. *Blood*, **2015**, 126, 1599-1599 | 2.2 | 1 |
| 131 | Driver Mutations and Prognosis in 1118 Patients with Primary Myelofibrosis. *Blood*, **2015**, 126, 2801-2801 | 2.2 | 1 |
| 130 | A 27-Gene NGS Panel in Primary Myelofibrosis Identifies ASXL1, CBL, RUNX1 and SRSF2 Mutations As Being Unfavorable and Absence of Any Non-Driver Mutation As Being Favorable to Survival. *Blood*, **2015**, 126, 350-350 | 2.2 | 1 |
| 129 | Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). *Blood*, **2016**, 128, 155-155 | 2.2 | 1 |
| 128 | Abnormal Karyotype and Prognosis in Polycythemia Vera: A Single Center Experience in 239 Informative Cases. *Blood*, **2016**, 128, 3115-3115 | 2.2 | 1 |
| 127 | U2AF1 Mutation Variants and Their Phenotypic and Prognostic Relevance in Primary Myelofibrosis. *Blood*, **2016**, 128, 4248-4248 | 2.2 | 1 |
| 126 | Number and Type of TET2 Mutations in Chronic Myelomonocytic Leukemia: Clinical and Prognostic Correlates. *Blood*, **2016**, 128, 4343-4343 | 2.2 | 1 |
| 125 | Risk Factors for Arterial Versus Venous Thrombosis in Polycythemia Vera: Single Center Experience in 587 Patients. *Blood*, **2016**, 128, 948-948 | 2.2 | 1 |
| 124 | Histologic and Immunohistochemical Study of Bone Marrow Monocytic Nodules in 21 Cases With Myelodysplasia. *American Journal of Clinical Pathology*, **2003**, 120, 874-881 | 1.9 | 1 |
| 123 | Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.. *Blood*, **2005**, 106, 624-624 | 2.2 | 1 |
| 122 | Anaplastic Angiocentric Glioma: A Report of Two Cases. *FASEB Journal*, **2008**, 22, 706.4 | 0.9 | 1 |

| | | | |
|---|---|---|---|
| 121 | High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?. *Blood*, **2018**, 132, 1693-1693 | 2.2 | 1 |
| 120 | A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800 | 2.2 | 1 |
| 119 | Novel Mutations in NOTCH and Altered Wnt/β-Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. *Blood*, **2016**, 128, 4103-4103 | 2.2 | 1 |
| 118 | Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. *Cancer Genetics*, **2020**, 241, 67-71 | 2.3 | 1 |
| 117 | Mayo Clinic experience with 1123 adults with acute myeloid leukemia. *Blood Cancer Journal*, **2021**, 11, 46 | 7 | 1 |
| 116 | CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. *Blood Cancer Journal*, **2021**, 11, 54 | 7 | 1 |
| 115 | Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. *Leukemia*, **2021**, 35, 3329-3333 | 10.7 | 1 |
| 114 | Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. *Genes Chromosomes and Cancer*, **2021**, 60, 678-686 | 5 | 1 |
| 113 | Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. *Genes Chromosomes and Cancer*, **2021**, 60, 108-111 | 5 | 1 |
| 112 | Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. *Case Reports in Hematology*, **2018**, 2018, 7456378 | 0.7 | 1 |
| 111 | De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. *British Journal of Haematology*, **2021**, 195, 413-416 | 4.5 | 1 |
| 110 | Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. *American Journal of Hematology*, **2021**, 96, 1450-1460 | 7.1 | 1 |
| 109 | Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.. *Blood Cancer Journal*, **2022**, 12, 44 | 7 | 1 |
| 108 | Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. *Journal of Hematopathology*, **2019**, 12, 99-104 | 0.4 | 0 |
| 107 | Anaplastic large-cell lymphoma (ALK-negative)-related heart failure and recurrence after heart transplantation. *Journal of Heart and Lung Transplantation*, **2020**, 39, 1156-1158 | 5.8 | 0 |
| 106 | Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?. *Blood Cancer Journal*, **2018**, 8, 8 | 7 | 0 |
| 105 | 20+ Years and Alive with Primary Myelofibrosis: Phenotypic Signature of Very Long-Lived Patients. *Blood*, **2018**, 132, 4301-4301 | 2.2 | 0 |
| 104 | SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. *Blood*, **2011**, 118, 460-460 | 2.2 | 0 |

| | | | |
|---|---|---|---|
| 103 | MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. *Blood Cancer Journal*, **2021**, 11, 184 | 7 | 0 |
| 102 | Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. *Blood*, **2021**, 138, 3771-3771 | 2.2 | 0 |
| 101 | Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. *Blood*, **2021**, 138, 3368-3368 | 2.2 | 0 |
| 100 | "Proliferative" Versus "Dysplastic" Chronic Myelomonocytic Leukemia: Molecular and Prognostic Correlates. *Blood*, **2016**, 128, 1987-1987 | 2.2 | 0 |
| 99 | Unique Clinical Epidemiologic Risk Factors Are Associated with Distinct Methylation Subgroups in Newly-Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2016**, 128, 1719-1719 | 2.2 | 0 |
| 98 | Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. *Blood*, **2016**, 128, 5534-5534 | 2.2 | 0 |
| 97 | Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. *Annals of Diagnostic Pathology*, **2020**, 48, 151588 | 2.2 | 0 |
| 96 | Genetic predictors of response to specific drugs in primary myelofibrosis. *Blood Cancer Journal*, **2018**, 8, 120 | 7 | 0 |
| 95 | Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. *Annals of Diagnostic Pathology*, **2021**, 53, 151761 | 2.2 | 0 |
| 94 | A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review. *Cancer Genetics*, **2021**, 258-259, 69-73 | 2.3 | 0 |
| 93 | Clonal compositions involving epigenetic regulator and splicing mutations in CHIP, CCUS, MDS, and CMML.. *Leukemia Research*, **2022**, 106818 | 2.7 | 0 |
| 92 | Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature.. *Annals of Diagnostic Pathology*, **2022**, 58, 151942 | 2.2 | 0 |
| 91 | Apparent coexistence of and fusions due to a nonproductive rearrangement in B-ALL.. *Leukemia and Lymphoma*, **2022**, 1-4 | 1.9 | 0 |
| 90 | RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large cell lymphoma.. *Histopathology*, **2022**, | 7.3 | 0 |
| 89 | Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. *Journal of Hematopathology*, **2019**, 12, 85-90 | 0.4 | |
| 88 | Test Samples and Laboratory Protocols **2006**, 292-339 | | |
| 87 | The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10 | 2.2 | |
| 86 | Heterogeneity of MYC Abnormalities in Multiple Myeloma. *Blood*, **2020**, 136, 2-3 | 2.2 | |

| | | |
|---|---|---|
| 85 | Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. *Blood*, **2020**, 136, 21-22 | 2.2 |
| 84 | Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma. *Blood*, **2020**, 136, 22-23 | 2.2 |
| 83 | Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. *Cancer Genetics*, **2021**, 260-261, 1-5 | 2.3 |
| 82 | Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. *Blood*, **2021**, 138, 1267-1267 | 2.2 |
| 81 | Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases. *Blood*, **2021**, 138, 3629-3629 | 2.2 |
| 80 | Cryptic t(6;11) KMT2A rearrangement in a pediatric acute myeloid leukemia patient detected by next-generation sequencing and dual-fusion FISH analysis. *Pediatric Blood and Cancer*, **2021**, e29428 | 3 |
| 79 | False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. *Blood*, **2021**, 138, 4101-4101 | 2.2 |
| 78 | Bone Marrow Histologic and Cytogenetic Changes during Leukemic Transformation of Myelofibrosis with Myeloid Metaplasia.. *Blood*, **2004**, 104, 4750-4750 | 2.2 |
| 77 | Low Incidence of FIP1L1-PDGFRA in Eosinophilic Patients and Long-Term Experience with Imatinib Therapy.. *Blood*, **2005**, 106, 2590-2590 | 2.2 |
| 76 | Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.. *Blood*, **2006**, 108, 4783-4783 | 2.2 |
| 75 | Idiopathic Eosinophilia with an Occult T-Cell Clone: Prevalence, FIP1L1-PDGFRA Status, and Clinical Course.. *Blood*, **2006**, 108, 2701-2701 | 2.2 |
| 74 | Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. *Blood*, **2006**, 108, 3587-3587 | 2.2 |
| 73 | Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.. *Blood*, **2007**, 110, 3504-3504 | 2.2 |
| 72 | Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449 | 2.2 |
| 71 | Predictors of Spleen and Anemia Response to Specific Drugs in Primary Myelofibrosis. *Blood*, **2018**, 132, 4300-4300 | 2.2 |
| 70 | Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort. *Blood*, **2018**, 132, 3987-3987 | 2.2 |
| 69 | Serum Erythropoietin Levels in Essential Thrombocythemia: Phenotypic and Prognostic Correlates. *Blood*, **2018**, 132, 3034-3034 | 2.2 |
| 68 | The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis. *Blood*, **2018**, 132, 1761-1761 | 2.2 |

| | | |
|---|---|---|
| 67 | Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide. *Blood*, **2018**, 132, 4287-4287 | 2.2 |
| 66 | Clinical and Molecular Models of Prognostication in Mastocytosis: Analysis Based on 580 Consecutive Cases. *Blood*, **2018**, 132, 582-582 | 2.2 |
| 65 | Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis. *Blood*, **2018**, 132, 1767-1767 | 2.2 |
| 64 | Cytogenetic Abnormalities in Systemic Mastocytosis: Who Subcategory-Specific Incidence and Prognostic Impact Among 348 Informative Cases. *Blood*, **2018**, 132, 3050-3050 | 2.2 |
| 63 | Myeloproliferative Neoplasms in Young Patients: The Mayo Clinic Experience with 361 Cases Age 40 Years or Younger. *Blood*, **2018**, 132, 3033-3033 | 2.2 |
| 62 | Cytogenetic Clonal Evolution in Myeloproliferative Neoplasms: Contexts and Prognostic Impact Among 650 Patients with Serial Bone Marrow Biopsies. *Blood*, **2018**, 132, 4291-4291 | 2.2 |
| 61 | Frequency of Acquired Genetic Mutations and Their Prognostic Impact on Patients with Incidental Finding of Isolated 20q- in Bone Marrow without Morphologic Evidence of a Myeloid Neoplasm. *Blood*, **2018**, 132, 4382-4382 | 2.2 |
| 60 | MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal. *Blood*, **2018**, 132, 3036-3036 | 2.2 |
| 59 | Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. *Blood*, **2018**, 132, 3100-3100 | 2.2 |
| 58 | Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. *Blood*, **2018**, 132, 2678-2678 | 2.2 |
| 57 | 1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. *Blood*, **2018**, 132, 2689-2689 | 2.2 |
| 56 | Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. *Blood*, **2018**, 132, 3044-3044 | 2.2 |
| 55 | A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy. *Blood*, **2018**, 132, 1771-1771 | 2.2 |
| 54 | Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 4396-4396 | 2.2 |
| 53 | Recurrent Chromosomal Abnormalities in Tumoral Lesions of Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia: A Large-Scale Fluorescent in-Situ Hybridization Study on Tissue Biopsy Sections. *Blood*, **2019**, 134, 4282-4282 | 2.2 |
| 52 | Differentiating between Hyperdiploidy and Pseudo-Hyperdiploidy in B-Lymphoblastic Leukemia Utilizing Low-Coverage Mate-Pair Sequencing. *Blood*, **2019**, 134, 5212-5212 | 2.2 |
| 51 | Vascular Events and Risk Factors for Thrombosis in Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). *Blood*, **2015**, 126, 4067-4067 | 2.2 |
| 50 | Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. *Blood*, **2015**, 126, 4062-4062 | 2.2 |

| | | |
|---|---|---|
| 49 | Molecular Correlates of Anemia in Primary Myelofibrosis. *Blood*, **2015**, 126, 4068-4068 | 2.2 |
| 48 | Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. *Blood*, **2015**, 126, 2875-2875 | 2.2 |
| 47 | Prognostic Interaction Between ASXL1 and TET2 Mutations in Chronic Myelomonocytic Leukemia. *Blood*, **2015**, 126, 2864-2864 | 2.2 |
| 46 | Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. *Blood*, **2015**, 126, 1401-1401 | 2.2 |
| 45 | Survival Trends in Essential Thrombocythemia in the Face of Changing Treatment Practices. *Blood*, **2015**, 126, 2805-2805 | 2.2 |
| 44 | Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176 | 2.2 |
| 43 | ASXL1 Mutations in Myelodysplastic Syndromes with 1% or More Ring Sideroblasts: Prevalence, Clinical Correlates and Prognostic Relevance. *Blood*, **2015**, 126, 2882-2882 | 2.2 |
| 42 | Prognostic Impact of Bone Marrow Fibrosis in Polycythemia Vera: Validation of the IWG-MRT Study and Additional Observations. *Blood*, **2016**, 128, 3129-3129 | 2.2 |
| 41 | Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. *Blood*, **2016**, 128, 1996-1996 | 2.2 |
| 40 | Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615 | 2.2 |
| 39 | Monocytosis in Polycythemia Vera: Clinical and Molecular Correlates. *Blood*, **2016**, 128, 4259-4259 | 2.2 |
| 38 | Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. *Blood*, **2016**, 128, 4086-4086 | 2.2 |
| 37 | Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 110-110 | 2.2 |
| 36 | Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269 | 2.2 |
| 35 | Next-Generation Sequencing in Myelodysplastic Syndromes: Prognostic Interaction Between Adverse Mutations and IPSS-R. *Blood*, **2016**, 128, 1986-1986 | 2.2 |
| 34 | Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255 | 2.2 |
| 33 | DNTM3A Mutations and Prognosis in Chronic Myelomonocytic Leukemia. *Blood*, **2016**, 128, 1988-1988 | 2.2 |
| 32 | Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. *Blood*, **2016**, 128, 3452-3452 | 2.2 |

| | | |
|---|---|---|
| 31 | The 2016 Revised World Health Organization Classification of 'Myelodysplastic Syndrome with Isolated Del(5q)'; Prognostic Implications of Single Versus Double Cytogenetic Abnormalities. *Blood* , **2016**, 128, 5542-5542 | 2.2 |
| 30 | Identification of Serum Lactate Dehydrogenase (LDH) As an Independent Prognostic Biomarker in Polycythemia Vera. *Blood*, **2016**, 128, 3111-3111 | 2.2 |
| 29 | Deletion 5q in AML: A Clinicopathological Description of 79 Cases from a Single Institution. *Blood*, **2008**, 112, 2523-2523 | 2.2 |
| 28 | Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. *Blood*, **2008**, 112, 1707-1707 | 2.2 |
| 27 | Rearrangements of IER3 Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes (MDS). *Blood*, **2008**, 112, 2679-2679 | 2.2 |
| 26 | Isolated Trisomy 8 in the Myelodysplastic Syndromes.. *Blood*, **2009**, 114, 2785-2785 | 2.2 |
| 25 | Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.. *Blood*, **2009**, 114, 1802-1802 | 2.2 |
| 24 | Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.. *Blood*, **2009**, 114, 3405-3405 | 2.2 |
| 23 | Prognostic Irrelevance of Ring Sideroblast Percentage in World Health Organization Defined Myelodysplastic Syndromes without Excess Blasts,. *Blood*, **2011**, 118, 3803-3803 | 2.2 |
| 22 | The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. *Blood*, **2011**, 118, 2568-2568 | 2.2 |
| 21 | Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. *Blood*, **2011**, 118, 3619-3619 | 2.2 |
| 20 | Immunoglobulin Free Light Chain Levels Predict Survival in Primary Myelofibrosis and De Novo Myelodysplastic Syndromes. *Blood*, **2011**, 118, 1756-1756 | 2.2 |
| 19 | Differential Prognostic Effect of IDH1 Versus IDH2 Mutations in Myelodysplastic Syndromes: A Mayo Clinic Study of 277 Patients. *Blood*, **2011**, 118, 971-971 | 2.2 |
| 18 | TP53 mutations and Polymorphisms in Primary Myelofibrosis,. *Blood*, **2011**, 118, 3840-3840 | 2.2 |
| 17 | Spliceosome Mutations Involving SRSF2, SF3B1 and U2AF35 in World Health Organization Defined Chronic Myelomonocytic Leukemia; Prevalence, Clinical Correlates and Prognosis. *Blood*, **2012**, 120, 1711-1711 | 2.2 |
| 16 | Phenotypic and Prognostic Correlates of Spliceosome Mutations (SRSF2, SF3B1, U2AF35) in Chronic Myelomonocytic Leukemia with □1% Ring Sideroblasts.. *Blood*, **2012**, 120, 2803-2803 | 2.2 |
| 15 | Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. *Blood*, **2012**, 120, 1875-1875 | 2.2 |
| 14 | Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients. *Blood*, **2012**, 120, 3790-3790 | 2.2 |

| | | |
|---|---|---|
| 13 | Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus. *Blood*, **2012**, 120, 430-430 | 2.2 |
| 12 | T(8;9)(p22;p24)/PCM1-JAK2 Activates SOCS2 and SOCS3 Via STAT5. *Blood*, **2012**, 120, 1567-1567 | 2.2 |
| 11 | The Effect of Number of Metaphases Studied and Abnormal Metaphase Percentage On Cytogenetic Risk Stratification in Primary Myelofibrosis. *Blood*, **2012**, 120, 1742-1742 | 2.2 |
| 10 | Normal Karyotype Primary Myelofibrosis (NK-PMF): Clinical and Molecular Prognostication In 690 Patients. *Blood*, **2013**, 122, 1587-1587 | 2.2 |
| 9 | U2AF1 mutations In Primary Myelofibrosis Cluster With Normal Karyotype and JAK2V617F and Are Strongly Associated With Anemia and Thrombocytopenia. *Blood*, **2013**, 122, 4060-4060 | 2.2 |
| 8 | Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. *Blood*, **2013**, 122, 4955-4955 | 2.2 |
| 7 | Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1334-1334 | 2.2 |
| 6 | Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. *Blood*, **2013**, 122, 2777-2777 | 2.2 |
| 5 | Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. *Blood*, **2013**, 122, 3016-3016 | 2.2 |
| 4 | Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms. *Leukemia Research*, **2019**, 87, 106264 | 2.7 |
| 3 | Calculator-free point-of-care prognostication in myelodysplastic syndromes. *American Journal of Hematology*, **2019**, 94, E99-E101 | 7.1 |
| 2 | Lymphoma-like double-hit genetic abnormalities ( and ) in a case of non-secretory multiple myeloma. *Leukemia and Lymphoma*, **2021**, 62, 243-246 | 1.9 |
| 1 | Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e710-e713 | 2 |